Cardinal Health, Inc. (CAH)

FairStock Score: 37/100 — MIXED

Key Financials

Strengths

• Essential distribution business with recurring revenue and genuine moat in healthcare supply chain
• Strong free cash flow generation of $5.4B demonstrates operational efficiency despite low margins
• Low beta of 0.62 provides portfolio diversification with defensive characteristics
• Market position serving 53,084 hospitals, pharmacies, and healthcare systems across US and internationally
• Quarterly revenue of $65.6B shows scale and market penetration in fragmented healthcare sector

Concerns

• Catastrophically low ROCE of 3.50% and net margin of 0.71% indicate value destruction and pricing powerlessness
• P/E of 29.95 is grossly overvalued for a mature, low-growth distribution business with compressed economics
• Altman Z-Score of 1.63 signals financial distress risk; Piotroski F-Score of 6/9 shows deteriorating fundamentals
• Extreme EV/EBITDA of 60.40x and FCF yield of 1.1% suggest market pricing in unrealistic future growth

AI Analysis

Cardinal Health presents a classic value trap masquerading as a stable business. On the surface, it appears sound—a $51.2B market cap healthcare distributor with $65.6B in quarterly revenue and $5.4B in free cash flow. The 0.62 beta suggests defensive characteristics. However, dig deeper and red flags emerge everywhere. A P/E of 29.95 is expensive for a low-margin distributor with a mere 0.71% net profit margin in Q4. The ROCE of 3.50% is abysmal—this business destroys shareholder value by deploying capital at returns far below our cost of capital. The EV/EBITDA of 60.40x is extraordinarily high, suggesting the market is pricing in growth that simply isn't materializing given the lack of revenue and profit growth metrics. The Piotroski F-Score of 6/9 indicates deteriorating financial health, while the Altman Z-Score of 1.63 places this in the 'grey zone' for bankruptcy risk. The FCF yield of 1.1% is pathetic for a mature business. Yes, Cardinal distributes essential pharmaceuticals and medical products—a real moat. But distribution is commoditized, margins are compressed, and consolidation has eliminated pricing power. I see a highly leveraged middleman caught between powerful suppliers and increasingly concentrated healthcare buyers. At $217.78, I'm not interested.

Bull Case

Cardinal Health could benefit from consolidation in healthcare creating pricing opportunities, or strategic initiatives in specialty pharmaceuticals and home healthcare expanding higher-margin segments. A cost restructuring program could improve margins toward 1.5-2%, significantly boosting ROCE and justifying current valuation multiples.

Bear Case

Continued margin compression from buyer consolidation, increased generic pharmaceutical competition, and working capital pressures could force dividend cuts. A recession impacting healthcare spending combined with the company's leverage could trigger a valuation reset to 12-15x EBITDA, implying 40-50% downside.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer